Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World

Zhejiang Hisun Pharmaceutical Co. Ltd.1,000 enrolled

Overview

TNF- α receptor inhibitors have been used widely in practice and are well developed in China. Anbainuo is a bio-similar recombinant TNF-α receptor: IgG Fc fusion protein, approved in 2015. Up to now, Anbainuo is well applied in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Although the phase II and III clinical trials both indicated that Anbainuo can effectively control the disease activity with good tolerance and safety in RA and AS patients, there is no sufficient clinical evidence in the real world. Thus, the objective of this study is to evaluate, under the actual conditions of use, dosing patterns of Anbainuo. Investigators plan to recruit 1000 adult patients with RA or AS and to follow them for 48 weeks. It is hypothesized that this study would reflect real clinical conditions (efficacy and safety assessment) of using Anbainuo in RA and AS patients.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Rheumatoid Arthritis Ankylosing Spondylitis

Interventions

recombinant TNF-α receptor: IgG Fc fusion protein

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * meet the diagnostic criteria of the American College of Rheumatology (ACR) (1987); * or meet the diagnostic criteria of ankylosing spondylitis (New York, modified in 1984); * older than 18; * Prepare to or already start to use Anbainuo. Exclusion Criteria: * any acute or chronic infection or the history of active tuberculosis * pregnant women or breast feeding women; * malignant tumor; * moderate to severe congestive heart failure (New York Heart Association, 3-4 grade); * allergic to Anbainuo.

Outcomes

Primary Outcomes

Percent of participants achieving clinical remission defined as a DAS28 ≥1.2

The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR), and general health (GH), both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 equals (=) \[0.56 multiplied by (\*) the square root (√) of TJC\] plus (+) \[0.28 \* √ of SJC\] + (0.70 \* the natural logarithm (ln) ESR in millimeters per hour (mm/h)\] + \[0.014 \* GH in mm visual analogue assessment (VAS)\]. A negative change from randomization indicated improvement.

Time frame: Up to week 48

Percent of participants achieving bath ankylosing spondylitis disease activity index (BASDAI) 50 response.

BASDAI subject assessment of discomfort, pain and fatigue was measured using a 100 millimeter Visual Analog Scale (VAS); range: 0=none to 100=very severe. BASDAI 50 response defined as at least a 50 percent (%) improvement (decrease) from baseline to observation (last observation carried forward) in the BASDAI. Baseline score minus score at observation divided by Baseline score \* 100 = \>=50%.

Time frame: Up to week 48

Secondary Outcomes

Change From baseline in the modified total Sharp score to week 48

he modified total sharp score is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint erosions and joint space narrowing.

Time frame: baseline and week 48